Answers are grounded in this paper and cite their sources.
Importance Respiratory syncytial virus (RSV) hospitalization rates are highest among children younger than 2 years. For certain high-risk children entering their second RSV season, the monoclonal antibody nirsevimab is recommended. Little is known regarding preexisting health conditions as risk factors for RSV-related respiratory failure in children during their second RSV season. Objective To describe children admitted to the pediatric intensive care unit (PICU) for severe RSV by classifying them by their nirsevimab eligibility status and preexisting health conditions, and comparing their demographic and clinical characteristics. Design, Setting, and Participants This cohort study analyzed US children aged 8 to 23 months admitted to the PICU in 30 pediatric hospitals in the 2023 to 2024 and 2024 to 2025 RSV seasons. All children had an RSV-positive result from a respiratory sample and received respiratory support with high-flow nasal cannula, noninvasive ventilation, or invasive mechanical ventilation. Analyses were based on the US criteria for second-season nirsevimab eligibility as recommended in August 2023. Exposure Preexisting health conditions potentially associated with increased risk of severe RSV disease. Patients were classified into 4 mutually exclusive groups of eligibility status and preexisting health conditions: (1) met nirsevimab eligibility criteria, (2) with other identified RSV risk conditions (with some evidence of increased risk for severe RSV), (3) with other preexisting conditions, and (4) with no preexisting conditions. Main Outcomes and Measures Patient demographic characteristics and level of respiratory support received were compared by level of preexisting health conditions. Results A total of 574 children (median [IQR] age, 1.2 [1.1-1.5] years; 317 males [55.2%]) were included. Overall, 47 patients (8.2%) met the nirsevimab eligibility criteria, 76 (13.2%) had other identified RSV risk conditions, 96 (16.7%) had other preexisting conditions, and 355 (61.8%) had no preexisting conditions. A higher proportion of children who met nirsevimab eligibility criteria required invasive mechanical ventilation vs children with other identified RSV risk conditions, those with other preexisting health conditions, or those with no preexisting health conditions (40.4% [19 of 47] vs 17.1% [13 of 76], 10.4% [10 of 96], 5.9% [21 of 355]; P for trend <.001). Conclusions and Relevance Among children admitted to the PICU for severe RSV, 8.2% met the nirsevimab eligibility criteria and 13.2% had other identified RSV risk conditions. These findings might help inform future deliberations regarding second RSV season recommendations for nirsevimab eligibility in the US.
No takes yet. Share an insight, caveat, or question.
Simeone et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: